Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | GALK1 | P51570 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15731795 | 0.87 | PIK3R1 (0.39) | RAD51EP300KAT2BMEN1KMT2A | |
| SCHEMBL5441070 | 0.87 | MEN1 (0.36) | AKR1C3ABL1MEN1KMT2ANPC1 | |
| SCHEMBL17576245 | 0.86 | AKR1C3 (0.44) | AKR1C3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29483984 | 0.86 | RAD51 (0.51) | AKR1C3RAD51MEN1KMT2AMAPT | |
| SCHEMBL6330031 | 0.86 | KMT2A (0.49) | AKR1C3RAD51MEN1KMT2ANPC1 | |
| SCHEMBL20050092 | 0.86 | ALDH1A1 (0.42) | EP300KAT2BMEN1KMT2ANPC1 | |
| SCHEMBL5447292 | 0.85 | MEN1 (0.38) | ABL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL186752 | 0.85 | LMNA (0.51) | AKR1C3RAD51MEN1KMT2ANPC1 | |
| SCHEMBL18028120 | 0.84 | ALDH1A1 (0.42) | RAD51EP300KAT2BMEN1KMT2A | |
| SCHEMBL20694863 | 0.84 | GSK3B (0.39) | RAD51EP300KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718779-B2 | Intermediate and polymorphs of 1-(4-methoxypheny1)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and process thereof | MSN LABORATORIES LIMITED (IN) | 2017-08-01 | — | — | US | claimed |
| US-20150353541-A1 | Novel intermediate and polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and process thereof | THIRUMALAI RAJAN SRINIVASAN (US) | 2015-12-10 | — | — | US | claimed |
| WO-2014108919-A2 | NOVEL INTERMEDIATE AND POLYMORPHS OF 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-c] PYRIDINE-3-CARBOXAMIDE AND PROCESS THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-07-17 | — | — | WO | claimed |
| EP-3875457-A1 | METHOD FOR PREPARING APIXABAN | Hana Pharm. Co. Ltd. (KR) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021147302-A1 | INTERMEDIATE OF APIXABAN AND PREPARATION METHOD THEREFOR | 浙江九洲药业股份有限公司 | 2021-07-29 | — | — | WO | disclosed |
| EP-3212620-B1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LTD FORMERLY JUBILANT LIFE SCIENCES DIVISION (IN) | 2020-11-25 | — | — | EP | disclosed |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| WO-2020085616-A1 | METHOD FOR PREPARING APIXABAN | 하나제약 주식회사 | 2020-04-30 | — | — | WO | disclosed |
| CN-110894196-A | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | 百时美-施贵宝控股爱尔兰无限公司 | 2020-03-20 | — | — | CN | disclosed |
| US-10336753-B2 | Process for the preparation of apixaban and intermediates thereof | UNICHEM LABORATORIES LIMITED (IN) | 2019-07-02 | — | — | US | disclosed |
| US-10208036-B2 | Process for the preparation of Apixaban and intermediates thereof | UNICHEM LABORATORIES LIMITED (IN) | 2019-02-19 | — | — | US | disclosed |
| EP-1379245-A1 | 1, 4, 5, 6-TETRAHYDROPYRAZOLO- 3, 4-C]-PYRID IN-7-ONES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | disclosed |
| WO-2003049681-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003049681-A2 | SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-28 | — | — | US | disclosed |
| WO-2002085356-A1 | 1, 4, 5, 6-TETRAHYDROPYRAZOLO-[3, 4-C]-PYRID IN-7-ONES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | AKR1C3 4261/4885ABL1 928/4885RAD51 1853/4885 |
| US-20020177713-A1 | 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors | SERPINC1, SERPINE1, F11 | AKR1C3 549/4885ABL1 2298/4885RAD51 3053/4885 |
| US-10336753-B2 | Process for the preparation of apixaban and intermediates thereof | HAX1, CYP4X1, HTRA1 | AKR1C3 364/4885ABL1 3918/4885RAD51 3392/4885 |
| US-10208036-B2 | Process for the preparation of Apixaban and intermediates thereof | HAX1, CYP4X1, HTRA1 | AKR1C3 364/4885ABL1 3918/4885RAD51 3392/4885 |
| US-20030181466-A1 | Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones | TFPI, TFPI2, F2 | AKR1C3 1259/4885ABL1 2487/4885RAD51 3630/4885 |
| US-20150353541-A1 | Novel intermediate and polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and process thereof | CYP3A4, CYP4B1, CYP1A1 | AKR1C3 842/4885ABL1 652/4885RAD51 1604/4885 |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | AKR1C3 1878/4885ABL1 3397/4885RAD51 1496/4885 |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, HABP2, CPB1 | AKR1C3 1995/4885ABL1 3097/4885RAD51 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.